Amgen Manufacturing, Limited

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Biological: Evolocumab
Drug: Placebo Ezetimibe
Drug: Ezetimibe
Drug: Placebo to Evolocumab

First Posted Date: 2015-12-18

Last Posted Date: 2020-11-10

Lead Sponsor: Amgen

Target Recruit Count: 61

Registration Number: NCT02634580

Locations: 🇯🇵
Research Site, Shinagawa-ku, Tokyo, Japan

Single Ascending Dose Study of AMG 570 in Healthy Subjects

Phase 1

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Biological: AMG 570
Biological: AMG 570 Matching Placebo

First Posted Date: 2015-12-02

Last Posted Date: 2024-05-14

Lead Sponsor: Amgen

Target Recruit Count: 56

Registration Number: NCT02618967

Locations: 🇺🇸
Research Site, Madison, Wisconsin, United States

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Biological: Evolocumab
Procedure: Low-density Lipoprotein Cholesterol (LDL-C) Apheresis

First Posted Date: 2015-10-26

Last Posted Date: 2022-11-30

Lead Sponsor: Amgen

Target Recruit Count: 39

Registration Number: NCT02585895

Locations: 🇬🇧
Research Site, Penarth, United Kingdom

Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)

Phase 2

Completed

Conditions: Stable Angina

Interventions: Drug: Placebo
Drug: Erenumab

First Posted Date: 2015-10-15

Last Posted Date: 2018-08-24

Lead Sponsor: Amgen

Target Recruit Count: 89

Registration Number: NCT02575833

Locations: 🇨🇭
Research Site, Geneva 14, Switzerland

Denosumab Safety Assessment in Multiple Observational Databases

Completed

Conditions: Osteoporosis

Interventions: Drug: denosumab
Drug: bisphosphonate

First Posted Date: 2015-08-11

Last Posted Date: 2024-11-04

Lead Sponsor: Amgen

Target Recruit Count: 517991

Registration Number: NCT02520362

Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611

Phase 1

Completed

Conditions: Hepatocellular Carcinoma
Liver Tumors
Cutaneous or Subcutaneous Lymph Node
Liver Metastases

Interventions: Drug: Talimogene Laherparepvec
Drug: Pembrolizumab

First Posted Date: 2015-07-28

Last Posted Date: 2024-08-06

Lead Sponsor: Amgen

Target Recruit Count: 127

Registration Number: NCT02509507

Locations: 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸
University of California Los Angeles, Santa Monica, California, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 29 locations

Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: etanercept pre-filled syringe subcutaneous injection
Drug: Oral methotrexate
Drug: Placebo for etanercept subcutaneous injection
Drug: Placebo for methotrexate
Dietary Supplement: Folic acid (non-investigational product)

First Posted Date: 2015-02-27

Last Posted Date: 2023-01-11

Lead Sponsor: Amgen

Target Recruit Count: 371

Registration Number: NCT02373813

Locations: 🇪🇸
Research Site, Bilbao, País Vasco, Spain

A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders

Phase 4

Completed

Conditions: Urea Cycle Disorder

Interventions: Drug: RAVICTI

First Posted Date: 2014-09-22

Last Posted Date: 2024-07-01

Lead Sponsor: Amgen

Target Recruit Count: 27

Registration Number: NCT02246218

Locations: 🇺🇸
Kaiser Permanente Regional Metabolic Center, Los Angeles, California, United States
🇺🇸
Stanford Center for Clinical & Translational Research & Education, Palo Alto, California, United States
🇺🇸
Shands at University of Florida, Gainesville, Florida, United States

and more 14 locations

Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Apremilast Immediate Release
Drug: Apremilast Modified Release 1
Drug: Apremilast Modified Release 4
Drug: Apremilast Modified Release 8
Drug: Apremilast Modified Release 11
Drug: Apremilast Modified Release 5
Drug: Apremilast Modified Release 12
Drug: Apremilast Modified Release 9
Drug: Apremilast Modified Release 2
Drug: Apremilast Modified Release 13
Drug: Apremilast Modified Release 3
Drug: Apremilast Modified Release 6
Drug: Apremilast Modified Release 14

First Posted Date: 2014-09-11

Last Posted Date: 2021-06-01

Lead Sponsor: Amgen

Target Recruit Count: 80

Registration Number: NCT02236988

Locations: 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

Phase 3

Completed

Conditions: Dyslipidemia

Interventions: Biological: Evolocumab
Drug: Placebo
Drug: Background Statin Therapy

First Posted Date: 2014-08-04

Last Posted Date: 2018-01-16

Lead Sponsor: Amgen

Target Recruit Count: 1974

Registration Number: NCT02207634

Locations: 🇬🇧
Research Site, Worcester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy